Abstract: The present disclosure provides methods and compositions for treating cancer (e.g., lung cancer) in a subject by increasing the expression of PDZ-LIM domain containing protein 2 (PDLIM2) in the subject, or a functional fragment thereof. The present disclosure further provides methods of using PDLIM2 as a marker for determining and monitoring a subject's responsiveness to an anti-cancer treatment, providing a prognosis about a cancer in a subject, and selecting an effective anti-cancer treatment for a subject. The present disclosure also provides in vitro methods of screening anti-cancer agents by assessing whether the expression of PDLIM2 is restored by an anti-cancer agent in a cancer cell.

Abstract: Disclosed are highly compliant bioelectronic neural interface devices with hydrogel adhesion. Example devices include adhesion-promoting functional groups that facilitate enhanced electrical contact with the nerve without the need for continuous application of pressure. A transfer process may be used to fabricate the device using a sacrificial material (e.g., polyacrylic acid (PAA)) that has tunable solubility in aqueous media, helping avoid the need for harsher release chemicals that may affect the properties of the hydrogel. The transfer process also helps achieve electrode contacts that are flush with a surface of the device and facilitate more intimate contact with the nerve. A gradual change in Young's modulus from a stiff contact pad region to a more compliant electrode contact region may be achieved via a varied amount of an epoxy-based material (such as SU-8 ) and with silicone-based material (such as polydimethylsiloxane (PDMS)) to encapsulate the device cable.